Literature DB >> 25272055

Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.

Gustavo Jabor Gozzi1, Zouhair Bouaziz, Evelyn Winter, Nathalia Daflon-Yunes, Dagmar Aichele, Abdelhamid Nacereddine, Christelle Marminon, Glaucio Valdameri, Waël Zeinyeh, Andre Bollacke, Jean Guillon, Aline Lacoudre, Noël Pinaud, Silvia M Cadena, Joachim Jose, Marc Le Borgne, Attilio Di Pietro.   

Abstract

A series of indeno[1,2-b]indole-9,10-dione derivatives were synthesized as human casein kinase II (CK2) inhibitors. The most potent inhibitors contained a N(5)-isopropyl substituent on the C-ring. The same series of compounds was found to also inhibit the breast cancer resistance protein ABCG2 but with totally different structure-activity relationships: a N(5)-phenethyl substituent was critical, and additional hydrophobic substituents at position 7 or 8 of the D-ring or a methoxy at phenethyl position ortho or meta also contributed to inhibition. The best ABCG2 inhibitors, such as 4c, 4h, 4i, 4j, and 4k, behaved as very weak inhibitors of CK2, whereas the most potent CK2 inhibitors, such as 4a, 4p, and 4e, displayed limited interaction with ABCG2. It was therefore possible to convert, through suitable substitutions of the indeno[1,2-b]indole-9,10-dione scaffold, potent CK2 inhibitors into selective ABCG2 inhibitors and vice versa. In addition, some of the best ABCG2 inhibitors, which displayed a very low cytotoxicity, thus giving a high therapeutic ratio, and appeared not to be transported, constitute promising candidates for further investigations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25272055     DOI: 10.1021/jm500943z

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

1.  Dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-4-ones as a new class of CK2 inhibitors.

Authors:  Mykola V Protopopov; Olga V Ostrynska; Sergiy A Starosyla; Maria A Vodolazhenko; Svetlana M Sirko; Nikolay Yu Gorobets; Volodymyr Bdzhola; Sergey M Desenko; Sergiy M Yarmoluk
Journal:  Mol Divers       Date:  2018-05-29       Impact factor: 2.943

2.  Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity.

Authors:  Gustavo Jabor Gozzi; Zouhair Bouaziz; Evelyn Winter; Nathalia Daflon-Yunes; Mylène Honorat; Nathalie Guragossian; Christelle Marminon; Glaucio Valdameri; Andre Bollacke; Jean Guillon; Noël Pinaud; Mathieu Marchivie; Silvia M Cadena; Joachim Jose; Marc Le Borgne; Attilio Di Pietro
Journal:  Drug Des Devel Ther       Date:  2015-07-03       Impact factor: 4.162

3.  Synthesis, Biological Evaluation and Molecular Modeling of Substituted Indeno[1,2-b]indoles as Inhibitors of Human Protein Kinase CK2.

Authors:  Faten Alchab; Laurent Ettouati; Zouhair Bouaziz; Andre Bollacke; Jean-Guy Delcros; Christoph G W Gertzen; Holger Gohlke; Noël Pinaud; Mathieu Marchivie; Jean Guillon; Bernard Fenet; Joachim Jose; Marc Le Borgne
Journal:  Pharmaceuticals (Basel)       Date:  2015-06-08

4.  Unexpected Binding Mode of a Potent Indeno[1,2-b]indole-Type Inhibitor of Protein Kinase CK2 Revealed by Complex Structures with the Catalytic Subunit CK2α and Its Paralog CK2α'.

Authors:  Jennifer Hochscherf; Dirk Lindenblatt; Benedict Witulski; Robin Birus; Dagmar Aichele; Christelle Marminon; Zouhair Bouaziz; Marc Le Borgne; Joachim Jose; Karsten Niefind
Journal:  Pharmaceuticals (Basel)       Date:  2017-12-13

5.  Development of Pharmacophore Model for Indeno[1,2-b]indoles as Human Protein Kinase CK2 Inhibitors and Database Mining.

Authors:  Samer Haidar; Zouhair Bouaziz; Christelle Marminon; Tuomo Laitinen; Antti Poso; Marc Le Borgne; Joachim Jose
Journal:  Pharmaceuticals (Basel)       Date:  2017-01-09

6.  ABCG2 confers promotion in gastric cancer through modulating downstream CRKL in vitro combining with biostatistics mining.

Authors:  Junqing Wang; Zhou Yunyun; Lu Wang; Xuehua Chen; Zhenggang Zhu
Journal:  Oncotarget       Date:  2017-01-17

7.  A π-Halogen Bond of Dibenzofuranones with the Gatekeeper Phe113 in Human Protein Kinase CK2 Leads to Potent Tight Binding Inhibitors.

Authors:  Alexander Schnitzler; Andreas Gratz; Andre Bollacke; Michael Weyrich; Uwe Kuckländer; Bernhard Wünsch; Claudia Götz; Karsten Niefind; Joachim Jose
Journal:  Pharmaceuticals (Basel)       Date:  2018-02-17

8.  Inhibition of Shiga toxin-converting bacteriophage development by novel antioxidant compounds.

Authors:  Sylwia Bloch; Bożena Nejman-Faleńczyk; Karolina Pierzynowska; Ewa Piotrowska; Alicja Węgrzyn; Christelle Marminon; Zouhair Bouaziz; Pascal Nebois; Joachim Jose; Marc Le Borgne; Luciano Saso; Grzegorz Węgrzyn
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

9.  A Simple and Efficient Synthesis of Highly Substituted Indeno[1,2-b]pyrrole and Acenaphtho[1,2-b]pyrrole Derivatives by Tandem Three-Component Reactions.

Authors:  Xiaodong Tang; Songlei Zhu; Ying Ma; Ren Wen; Lanqi Cen; Panwei Gong; Jing Wang
Journal:  Molecules       Date:  2018-11-20       Impact factor: 4.411

10.  Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor.

Authors:  Ehab El-Awaad; Robin Birus; Christelle Marminon; Zouhair Bouaziz; Laurens Ballentin; Dagmar Aichele; Marc Le Borgne; Joachim Jose
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.